Following the identification of the role of the apolipoprotein E (APOE) gene polymorphism in Alzheimer's disease (AD), this gene was examined in cerebral amyloid angiopathy (CAA). As in AD, the APOE epsilon 4 allele was found to be associated with CAA. Lobar intracerebral hemorrhage is the major clinical manifestation of CAA. Initial studies on a small number of patients with CAA-related hemorrhage (CAAH) identified overrepresentation of APOE epsilon 4. However, it became clear that confounding bias from concomitant AD and the need for pathologically confirmed cases of CAAH would also have to be considered. A larger series of pathologically confirmed cases of CAAH, also assessed for AD pathology, found a surprising overrepresentation of the APOE epsilon 2 allele. Because of the association between CAA and AD, it might have been predicted that patients with CAAH would have a low, rather than a high, epsilon 2 frequency. The overrepresentation of APOE epsilon 2 was present both in patients with and without AD, whereas a high epsilon 4 frequency correlated with concomitant AD. Further studies found that overrepresentation of APOE epsilon 2 is specific for CAAH and is not found in intracranial hemorrhages due to other causes. In CAAH, APOE epsilon 2 may interact with putative risk factors for hemorrhage, including antiplatelet/anticoagulant medication, minor head trauma, and hypertension. Several microvascular abnormalities in amyloid-laden blood vessels have been assumed to antedate CAAH and increase its likelihood. APOE epsilon 2 has now been found to be associated with some of these vascular abnormalities, specifically a "double-barrel" appearance and fibrinoid necrosis. The currently favored interpretation is that APOE epsilon 4 enhances deposition of amyloid-beta protein in the walls of cerebral blood vessels, whereas epsilon 2 is a risk factor for hemorrhage from amyloid-laden blood vessels by promoting specific "CAA-associated vasculopathies."
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1749-6632.2000.tb06366.x | DOI Listing |
Background: The Apolipoprotein epsilon 4 allele (APOE ε4) gene is known as the most prevalent genetic risk factor for Alzheimer's disease (AD). However, many lifestyle risk factors that are modifiable influence the development of AD. Reducing the prevalence of risk factors can prevent or delay up to 33% of AD cases.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Schleswig-Holstein, Germany.
Background: In 2023, the FDA approved LEQEMBI, a monoclonal antibody therapy targeting beta-amyloid plaques, for patients with early-stage Alzheimer's disease (AD). However, anti-amyloid drug trials demonstrated an elevated risk for amyloid-related imaging abnormalities with cerebral edema (ARIA-E) in carriers of the AD risk allele apolipoprotein E epsilon 4 (APOE-ɛ4), especially in ɛ4/ɛ4 homozygous individuals. Here, we report on the evaluation of a new real-time polymerase chain reaction (PCR) test for APOE genotyping.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, Los Angeles, Los Angeles, CA, USA.
Background: We recently reported that subjects who had worsening sleep over time had a clear worsening of both memory and brain metabolism compared to subjects whose sleep improved over time, and metabolic decline was particularly significant in the posterior cingulate cortex (PCC) (Alzheimer's Dement. 2023; 19(Suppl. 24):e082867), an area of the brain that metabolically declines in the earliest stages of Alzheimer's disease.
View Article and Find Full Text PDFFront Public Health
December 2024
Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Introduction: is regarded as the most significant genetic contributor linked to mild cognitive impairment (MCI) and Alzheimer's disease (AD). Daily life elements might also influence cognitive abilities to some extent. This research aimed to investigate whether carrying alters the effects of lifestyle on cognitive ability.
View Article and Find Full Text PDFGenes (Basel)
October 2024
Clinical Neurochemistry Unit and Biobank, IRCCS Santa Lucia Foundation, Via Ardeatina, 306/354, 00179 Rome, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!